A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer

NCT05091567 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

660

Enrollment

INDUSTRY

Sponsor class

Conditions

Small-Cell Lung Cancer

Interventions

DRUG: Atezolizumab
DRUG: Lurbinectedin
DRUG: Carboplatin
DRUG: Etoposide

Sponsor

Hoffmann-La Roche

Collaborators

[object Object]